Trial reportPloS one2012
Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.
Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02336074 (Research In Viral Eradication of HIV Reservoirs), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research In Viral Eradication of HIV Reservoirs
Who cites it
35 citing papers in PubMed.
- Long-term effect of temporary ART initiated during primary HIV-1 infection on viral persistence.Nature communications · 2025Trial
- Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men.AIDS (London, England) · 2019Trial
- Antiretroviral Therapy Changes for Medicare Beneficiaries With HIV Transitioning to Long-Term Care.JAMA network open · 2025Article
- Current State of Therapeutics for HTLV-1.Viruses · 2024Review
- Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial.Journal of virus eradication · 2024Article
- First terror bird footprints reveal functionally didactyl posture.Scientific reports · 2023Article
- Review
- Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients.Frontiers in cellular and infection microbiology · 2022Article
- Serodiscordance predictors among couples in the HIV context: implications for health care.BMC public health · 2021Article
- Block-And-Lock: New Horizons for a Cure for HIV-1.Viruses · 2020Review
- Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.AIDS (London, England) · 2020Article
- Assessing the Quality of Human Immunodeficiency Virus Care in Nursing Homes.Journal of the American Geriatrics Society · 2020Article
- Integrase strand-transfer inhibitors for treatment of early HIV infection: A case series.Medicine · 2019Article
- Control of viral infections by epigenetic-targeted therapy.Clinical epigenetics · 2019Review
- New Frontiers in Measuring and Characterizing the HIV Reservoir.Frontiers in microbiology · 2019Review
- TZA: a novel assay for measuring the latent HIV-1 reservoir.Expert review of molecular diagnostics · 2017Review
- Modelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxis.Evolutionary applications · 2017Article
- Antiretroviral Therapy Interruption Among HIV Postive People Who Use Drugs in a Setting with a Community-Wide HIV Treatment-as-Prevention Initiative.AIDS and behavior · 2017Article
- Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.AIDS (London, England) · 2016Article
- Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers.PLoS pathogens · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesThe magnitude of HIV viral rebound following ART cessation has consequences for clinical outcome and onward transmission. We compared plasma viral load (pVL) rebound after stopping ART initiated in primary (PHI) and chronic HIV infection (CHI).
designTwo populations with protocol-indicated ART cessation from SPARTAC (PHI, n = 182) and SMART (CHI, n = 1450) trials.
methodsTime for pVL to reach pre-ART levels after stopping ART was assessed in PHI using survival analysis. Differences in pVL between PHI and CHI populations 4 weeks after stopping ART were examined using linear and logistic regression. Differences in pVL slopes up to 48 weeks were examined using linear mixed models and viral burden was estimated through a time-averaged area-under-pVL curve. CHI participants were categorised by nadir CD4 at ART stop.
resultsOf 171 PHI participants, 71 (41.5%) rebounded to pre-ART pVL levels, at a median of 50 (95% CI 48-51) weeks after stopping ART. Four weeks after stopping treatment, although the proportion with pVL ≥ 400 copies/ml was similar (78% PHI versus 79% CHI), levels were 0.45 (95% CI 0.26-0.64) log(10) copies/ml lower for PHI versus CHI, and remained lower up to 48 weeks. Lower CD4 nadir in CHI was associated with higher pVL after ART stop. Rebound for CHI participants with CD4 nadir >500 cells/mm(3) was comparable to that experienced by PHI participants.
conclusionsStopping ART initiated in PHI and CHI was associated with viral rebound to levels conferring increased transmission risk, although the level of rebound was significantly lower and sustained in PHI compared to CHI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.